HEMO Hemogenyx Pharmaceuticals Plc

LSE · GB · Healthcare · Biotechnology · hemogenyx.com

700.00GBp+7.69%Mkt Cap: 52.48M $P/E: —Today

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company'…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap52.48M USD

Enterprise Value45.02M USD

Revenue (TTM)—

Gross Profit-1.01M USD

Net Income (TTM)-10.61M USD

Revenue/Share—

Last Price700.00 GBp

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees16

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-3.58

EV/Revenue—

P/S—

P/B9.67

EPS (TTM)-1.31

EPS (Forward)—

52W Range

356.0035% of range1345.00

52W High1345.00 GBp

52W Low356.00 GBp

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-816.50%

ROA-233.73%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-3.75M USD

CapEx (TTM)4.26K USD

FCF Margin—

FCF Yield-3.06%

Net Debt-2.97M USD

Net Debt/EBITDA0.24

Balance Sheet

Debt/Equity1.68

Current Ratio4.04

Quick Ratio4.04

Book Value/Sh0.67 GBp

Cash/Share0.67 GBp

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 GBp

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Splits

Last Split1:400

Split DateDec 13, 2024

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.6.90M

Float5.27M

Insiders29.02%

Institutions0.40%

Technical

SMA 50558.51 (+25.3%)

SMA 200751.08 (-6.8%)

Beta1.49

S&P 52W Chg14.58%

Avg Vol (30d)23.76K

Avg Vol (10d)21.47K

Technical Indicators

RSI (14)68.9

MACD-11.5736

MACD Signal-34.4545

MACD Hist.+22.8809

BB Upper586.10 GBp

BB Middle484.63 GBp

BB Lower383.15 GBp

BB Width41.88%

ATR (14)68.91 GBp

Vol Ratio (20d)3.94x